| Literature DB >> 27341037 |
Kamal Razavi-Azarkhiavi1, Milad Iranshahy2, Amirhossein Sahebkar3, Kobra Shirani4, Gholamreza Karimi5,6.
Abstract
Although doxorubicin (DOX) is among the most widely used anticancer agents, its clinical application is hampered owing to its cardiotoxicity. Adjuvant therapy with an antioxidant has been suggested as a promising strategy to reduce DOX-induced adverse effects. In this context, many phenolic compounds have been reported to protect against DOX-induced cardiotoxicity. The cardioprotective effects of phenolic compounds are exerted via multiple mechanisms including inhibition of reactive oxygen species generation, apoptosis, NF-κB, p53, mitochondrial dysfunction, and DNA damage. In this review, we present a summary of the in vitro, in vivo, and clinical findings on the protective mechanisms of phenolic compounds against DOX-induced cardiotoxicity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27341037 DOI: 10.1080/01635581.2016.1187280
Source DB: PubMed Journal: Nutr Cancer ISSN: 0163-5581 Impact factor: 2.900